MEDIGENE AG NA O.N. news, videos and press releases
For more news please use our advanced search feature.
MEDIGENE AG NA O.N. - More news...
MEDIGENE AG NA O.N. - More news...
- Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
- Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
- Medigene to Present at Upcoming Conferences
- Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
- Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
- Medigene AG reports Financial Results and Business Update for Q1 2024
- Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
- Medigene to Present at Upcoming Scientific Conferences
- Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
- Medigene AG Secures European Patent for its iM-TCR Technology
- Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
- Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Medigene AG to report full year 2023 financial results on March 28, 2024
- Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
- Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
- Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
- Medigene to Present at Upcoming Conferences
- Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
- Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference
- Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway
- Medigene amends 2023 financial guidance
- Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11
- Medigene Reports Financial Results and Corporate Update for Q3 2023
- Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing
- Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023
- Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
- Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
- Medigene AG to present at the Baader Investment Conference 2023
- Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference
- Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes